Latest news with #Durvalumab
Deccan Herald
4 days ago
- Health
- Deccan Herald
AstraZeneca gets CDSCO nod for drug to treat muscle-invasive bladder cancer
The newly approved indication from the Central Drugs Standard Control Organisation (CDSCO) allows the use of Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment for the treatment of adult patients with muscle-invasive bladder cancer (MIBC), the company said in a statement.
Business Upturn
5 days ago
- Business
- Business Upturn
Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug
By Aman Shukla Published on July 15, 2025, 09:47 IST AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India's Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import and sell its cancer drug Durvalumab (branded as Imfinzi) in India for an additional use. This new approval covers two dosage forms—120 mg/2.4 ml and 500 mg/10 ml—and expands Imfinzi's indication to treat adult patients with muscle invasive bladder cancer (MIBC). Specifically, the drug can now be used in combination with gemcitabine and cisplatin as a neoadjuvant (pre-surgery) treatment. After surgery (radical cystectomy), Imfinzi can continue as a standalone adjuvant (post-surgery) therapy. The expanded label marks a significant milestone for AstraZeneca in India's oncology market, particularly in bladder cancer treatment. The company can now begin marketing Imfinzi for this new use, subject to any further clearances that may be needed. Imfinzi is already approved globally for other cancer indications, including lung and biliary tract cancers. This latest CDSCO approval adds another layer to its growing clinical footprint in India. AstraZeneca Pharma shares opened at ₹9,195.00 and touched a high of ₹9,650.50 during the day. The stock did not fall below its opening price, marking ₹9,195.00 as the low. Over the past year, the stock has seen a 52-week high of ₹10,691.00 and a low of ₹6,220.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
5 days ago
- Business
- Business Upturn
Top stocks in focus on July 15; Tata Technologies, HCL Tech, RVNL, AstraZeneca Pharma, RailTel and more
By Aman Shukla Published on July 15, 2025, 08:10 IST Indian markets extended their losing streak for the fourth day on Monday. he Nifty 50 slipped 67.55 points to close at 25,082.30, while the Sensex fell 247.01 points to end at 82,253.46. Here's a look at notable stocks in focus today: Stocks to Watch – July 15, 2025 RVNL – Received ₹447 crore order from Delhi Metro for Phase-IV viaduct construction. Best Agrolife – CFO highlights patent wins and branded business growth to aid margins. Sun Pharma – Launched LEQSELVI in the U.S. for treating severe alopecia areata. AstraZeneca Pharma – Received CDSCO approval to market Durvalumab for additional use in India. Tara Chand Infra – Won ₹81.51 crore consignment and handling contract from SAIL. Kranti Industries – Cleared to begin commercial production of gearbox housings for Bonfiglioli. Aarvi Encon – Received a new work order from a leading Indian infrastructure company. Yatharth Hospital – Opened a new facility in Model Town, Delhi on July 14. GG Automotive – Q1 net profit rose to ₹2.6 crore; revenue at ₹28 crore vs ₹25.32 crore YoY. Unicommerce – Partnered with Sennheiser to improve online sales and reduce cart abandonment. RailTel – Received ₹264.07 crore order from East Central Railway for Kavach deployment. Fischer Medical Ventures – Collaborating with Indonesia's Jember on AI-based X-ray systems for TB care. Namo eWaste – Launched lithium-ion battery recycling plant in Nashik, Maharashtra. Den Networks – Q1 profit at ₹53.6 crore vs ₹43.3 crore; revenue dipped slightly YoY. Rallis India – Q1 profit surged to ₹95 crore; revenue up to ₹960 crore vs ₹783 crore YoY. Power Mech Projects – Bagged two new orders worth over ₹550 crore from SJVN and Jhabua Power. Deepak Fertilizers – Signed regasification agreement with Petronet LNG. Sambhav Steel – Reported 47% YoY growth in value-added product volumes to 79,717 tonnes. HCL Tech – Revenue and EBIT largely in line with expectations. Tata Technologies – Posted higher-than-expected Q1 profit and revenue. Brigade Enterprises – To raise up to ₹1,500 crore via private placement of NCDs. Bandhan Bank – Appointed Biju E Punnachalil as Chief Risk Officer for a 3-year term. Karnataka Bank – Raghavendra S Bhat named new MD & CEO, effective July 16. KEC International – Record date set as July 25 for ₹5.50 per share final dividend. Fortis Healthcare – Record date of July 25 for ₹1 per share final dividend. Hawkins Cookers – Set July 30 as record date for dividend payment. BPCL – Appointed Subhankar Sen as Director (Marketing). Nilkamal – Signed agreements to acquire healthcare furniture business from Imedfurns. ONGC – Named Om Prakash Sinha as Director (Exploration). Dhampur Sugar Mills – Issued commercial papers worth ₹100 crore. MTNL – CMD charge for Robert J Ravi extended by another three months. Valor Estate – Appointed Rahul Pandit as CEO and Ajit Jain as CFO at Advent Hotels. Oberoi Realty – ₹919 crore resolution plan for Hotel Horizon approved. LIC – Appointed R Doraiswamy as CEO & Managing Director. JP Power – Circuit filter revised from 20% to 10%. Raymond Realty, Globe Civil – Circuit filters changed from 5% to 20%. Aditya Birla Real Estate – Goes ex-dividend today; ₹2 per share. NELCO – Posted YoY drop in profit to ₹1.8 crore vs ₹4.56 crore; revenue steady. Tejas Networks – Reported net loss of ₹190 crore; revenue dropped sharply YoY. Shiva Mills – Long-term bank rating downgraded to CARE BBB; Stable. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash AstraZeneca PharmaHCL TechRailTelRVNLtata technologies Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
News18
5 days ago
- Business
- News18
Stocks To Watch: HDFC Life, HDB Financial, HCL Tech, RVNL, Sun Pharma, And Others
Last Updated: Stocks to watch: Shares of firms like HDFC Life, HDB Financial, HCL Tech, RVNL, Sun Pharma, and others will be in focus on Tuesday's trade Stocks to Watch on July 15, 2025: Markets opened the week on a volatile note, extending recent losses to close nearly half a percent lower. On Tuesday, attention will remain on a slew of companies announcing their first-quarter earnings, including HDFC Life, HDB Financial, HCL Tech, Tata Technologies, and Rallis India, among others. Q1 Results Today Key earnings are expected from HDFC Life, ICICI Lombard, ICICI Prudential, HDB Financial Services, Bank of Maharashtra, and Just Dial. HCL Technologies HCLTech revised its EBIT margin guidance for FY26 to 17–18%, down from 18–19%, following margin pressure in Q1. EBIT margins declined 160 basis points QoQ to 16.3% for the June quarter. Tata Technologies The company posted a 10% YoY drop in net profit at Rs 170 crore, with USD revenue down 2.1% QoQ and constant currency revenue falling 4.6%. Rail Vikas Nigam Ltd received a Letter of Award from DMRC to construct a 7.298 km viaduct and seven metro station platforms under Delhi Metro Phase-IV. RailTel bagged a Rs 264 crore order from East Central Railway to implement the Kavach collision avoidance system across 607 km. AstraZeneca Pharma Received approval from CDSCO to import and market Durvalumab (Imfinzi) in India for an additional indication in cancer treatment. Sun Pharma Launched LEQSELVI 8 mg tablets in the US for severe alopecia areata, following a litigation settlement with Incyte Corporation. Power Mech Projects Won two O&M contracts worth Rs 551.35 crore, including a major project for SJVN's Buxar plant in Bihar. Oberoi Realty The CoC of Hotel Horizon approved a Rs 919 crore resolution plan submitted by a consortium including Oberoi Realty. Inox Wind The board will meet on July 17 to consider fundraising through equity or other instruments. LIC R Doraiswamy has officially taken charge as CEO & MD of LIC for a three-year term, ending August 2028. Tejas Networks Posted a net loss of Rs 193.9 crore for Q1 FY26, compared to a Rs 77.5 crore profit a year earlier. Revenue dropped 87% YoY, largely due to BSNL-related delays. Deepak Fertilisers Signed a Rs 1,200 crore regasification contract with Petronet LNG. Meson Valves India Received an order worth Rs 46.26 lakh from Mazagon Dock to supply submarine fuel system components. Disclaimer:Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions. view comments First Published: July 15, 2025, 08:02 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Standard
02-07-2025
- Business
- Business Standard
AstraZeneca Pharma gets CDSCO approval to import Durvalumab Solution
AstraZeneca Pharma India said that it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab Solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi). Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR). AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. The companys consolidated net profit jumped 57.7% to Rs 62.27 crore on 25.4% increase in net sales to Rs 480.48 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.13% to Rs 8,886.50 on the BSE.
